Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2026-03-06 @ 2:04 PM
Study NCT ID:
NCT00538005
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2007-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Sponsor:
San Diego Pacific Oncology & Hematology Associates
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
CDR0000551557
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None